Document is current
Any future updates will be listed below
-
Authors
Strayer, Thomas E.
Spalluto, Lucy B.
Burns, Abby
Lindsell, Christopher J.
Henschke, Claudia I.
Yankelevitz, David F.
Moghanaki, Drew
Dittus, Robert S.
Vogus, Timothy J.
Audet, Carolyn
Kripalani, Sunil
Roumie, Christianne L.
Lewis, Jennifer A. https://orcid.org/0000-0002-4234-1765
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences (HL137943)
Vanderbilt-Ingram Cancer Center (CA68485)
American Society of Clinical Oncology (YIA-9865677411)
LUNGevity Foundation (2021-08)
Agency for Healthcare Research and Quality (HS026122, K12HS026395)
Bristol-Myers Squibb
Office of Rural Health
National Cancer Institute (UL1TR002243)
- License Information
-
More Information
Article History
Received: 19 July 2022
Accepted: 20 December 2022
First Online: 12 January 2023
Declarations
:
: This study was approved by VA Central Institutional Review Board (C-IRB E19-05), the VA Tennessee Valley Healthcare System Research & Development Committee, the VA Organizational Assessment Subcommittee, and the VA Office of Labor and Management Relations (national union approval).
: Not applicable.
: LBS and JAL serve on the Steering Committee for the VA Tennessee Valley Healthcare System Lung Cancer Screening Program; JAL is a co-director of the VA Tennessee Valley Healthcare System Lung Cancer Screening Program. None of the authors receives financial compensation for these roles. DFY is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest including measurement of nodules. Some of these, which are owned by Cornell Research Foundation (CRF), are non-exclusively licensed to General Electric. As an inventor of these patents, DFY is entitled to a share of any compensation which CRF may receive from its commercialization of these patents. He is also an equity owner in Accumetra, a privately held technology company committed to improving the science and practice of image-based decision-making. DFY also serves on the advisory board of GRAIL. CIH is the President and serves on the board of the Early Diagnosis and Treatment Research Foundation. She receives no compensation from the Foundation. The Foundation is established to provide grants for projects, conferences, and public databases for research on early diagnosis and treatment of diseases. CIH is also a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest which are owned by the Cornell Research Foundation (CRF). Since 2009, CIH does not accept any financial benefit from these patents including royalties and any other proceeds related to the patents or patent applications owned by CRF.
